<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880369</url>
  </required_header>
  <id_info>
    <org_study_id>R174-A11507-17-S52</org_study_id>
    <nct_id>NCT04880369</nct_id>
  </id_info>
  <brief_title>Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression</brief_title>
  <acronym>DAGMAR</acronym>
  <official_title>DAGMAR: Phytoestrogens and Breast Cancer - Effects of Phytoestrogens on Markers of Disease Progression and Gene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Cancer Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to investigate if soy isoflavones and lignans affect markers of disease&#xD;
      progression and gene expression among breast cancer patients receiving neo-adjuvant treatment&#xD;
      in a three arm, double-blinded, randomized placebo-controlled trial (RCT) comparing: soy&#xD;
      isoflavone supplementation, lignan supplementation, and placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Disapproved by relevant Danish ethical committee&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study planned to include 150 women.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ki-67</measure>
    <time_frame>Change from baseline (diagnosis of breast cancer) to end-of-study (surgery): Approx. four months (neo-adjuvant setting)</time_frame>
    <description>Ki-67 can be measured using immunohistochemistry (IHC) and using the transcript from gene expression data (see secondary outcomes). As the latter is superior and less biased, the Ki-67 based on the transcript will be used as primary measure of Ki67.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apoptosis marker caspase-3</measure>
    <time_frame>Change from baseline (diagnosis of breast cancer) to end-of-study (surgery): Approx. four months (neo-adjuvant setting)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proliferation Index</measure>
    <time_frame>Change from baseline (diagnosis of breast cancer) to end-of-study (surgery): Approx. four months (neo-adjuvant setting)</time_frame>
    <description>Based on expression data from 79 genes encoding proliferative and cell cycle markers. Gene expression will be analyzed using a microarray (GeneChip® Human Genome U133 Plus 2.0 Array, Affymetrix, USA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>Change for completion of first questionnaire (shortly after diagnosis) to second questionnaire (close to time of surgery). Approx. four months (neo-adjuvant setting)</time_frame>
    <description>Well-being</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fecal microbiome:</measure>
    <time_frame>Change measured in first fecal sample (shortly after diagnosis) to second fecal sample (close to time of surgery). Approx. four months (neo-adjuvant setting)</time_frame>
    <description>The microbial community composition will be characterized using the 16sRNA method (Illumina MiSeq Platform).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Lignan capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule/day from baseline to end-of-follow-up (approx. 4 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoflavones capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule/day from baseline to end-of-follow-up (approx. 4 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule/day from baseline to end-of-follow-up (approx. 4 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <description>Commercially available dietary supplement (capsule) containing 60 mg isoflavones (genistein, daidzein and glycitein).</description>
    <arm_group_label>Isoflavones capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lignans</intervention_name>
    <description>Commercially available dietary supplement (capsule) containing 63 mg lignans (secoisolaricirecinol)</description>
    <arm_group_label>Lignan capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo capsules are supplied and packaged by Region Hovedstadens Apotek (Denmark) and will contain lactose monohydrate, potato starch, gelatin, magnesium stearate and talc.</description>
    <arm_group_label>Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with breast cancer at &quot;Brystkirurgisk Afdeling&quot; at Rigshospitalet and Herlev&#xD;
             Hospitals (within the last 30 days).&#xD;
&#xD;
          -  Advised (and accepted) to receive neo-adjuvant treatment&#xD;
&#xD;
          -  Primary unilateral breast cancer&#xD;
&#xD;
          -  Treatment is expected to be curative&#xD;
&#xD;
          -  Is expected to be able to attend surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to soy&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Not understanding Danish (patient material and questionnaires are in Danish)&#xD;
&#xD;
          -  Prior diagnosis of breast cancer&#xD;
&#xD;
          -  Use of dietary supplements containing lignans or isoflavones three months prior to&#xD;
             diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Cancer Society</investigator_affiliation>
    <investigator_full_name>Cecilie Kyrø</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Phytoestrogens</keyword>
  <keyword>Isoflavones</keyword>
  <keyword>Lignans</keyword>
  <keyword>Gene expression</keyword>
  <keyword>Breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon approval from relevant authorities and in accordance with the law</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_access_criteria>Please request this information from PI Cecilie Kyrø, Ceciliek@cancer.dk</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

